Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
April 04, 2022 07:30 ET
|
Inozyme Pharma Inc.
- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest dose cohort (0.2 mg/kg) – - PPi increased in all three patients to levels...
Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights
March 15, 2022 17:24 ET
|
Inozyme Pharma Inc.
– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway – – Expect to enroll first patient in Phase 1/2 trial of INZ-701 for ABCC6 Deficiency in the second quarter of 2022 – –...
Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference
March 01, 2022 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
November 15, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 09, 2021 16:05 ET
|
Inozyme Pharma Inc.
– On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 – – Cash,...
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting
October 04, 2021 07:30 ET
|
Inozyme Pharma Inc.
- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets - - Preclinical data...
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of...
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
August 11, 2021 06:00 ET
|
Inozyme Pharma Inc.
- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency – – Clinical Trial Application in Europe accepted for Phase 1/2 trial of...